Cargando…

2163. Risk Factors for Carbapenem-Resistant Gram-Negative Bloodstream Infections (BSI) in U.S. Hospitals (2010–2015)

BACKGROUND: Carbapenem-resistant (CR) Gram-negative (GN) infections are associated with higher mortality and extended hospital stays. Time to effective antibiotic treatment is important for patient survival. Classifying the risk factors for CR GN BSI before identification and susceptibility results...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Bin, Echols, Roger, Rudin, Deborah, Morgan, Gareth, Nagata, Tsutae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253812/ http://dx.doi.org/10.1093/ofid/ofy210.1819

Ejemplares similares

1191. Prevalence and Microbiology of Carbapenem Resistance Among Six Gram-Negative Pathogens in Bloodstream Infections in US Hospitals, 2010–2015
por: Lodise, Thomas P, et al.
Publicado: (2018)

Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa
por: Cai, Bin, et al.
Publicado: (2017)

681. Epidemiology and Outcomes of Patients with Carbapenem-Resistant Bloodstream Infection in United States Hospitals, 2010–2015
por: Echols, Roger, et al.
Publicado: (2018)

681. Epidemiology and Outcomes of Patients with Carbapenem-Resistant Bloodstream Infection in United States Hospitals, 2010–2015
por: Echols, Roger, et al.
Publicado: (2018)

Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance
por: Echols, Roger, et al.
Publicado: (2019)

US FDA’s Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication
por: Echols, Roger M, et al.
Publicado: (2021)

1271. Efficacy and Safety of Cefiderocol and Best Available Therapy in Patients with Serious Infections Caused by Carbapenem-Resistant Gram-Negative Infections: Results of the Pathogen-Focused Phase 3 CREDIBLE-CR Study
por: Bassetti, Matteo, et al.
Publicado: (2020)

Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens – The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study
por: Bassetti, Matteo, et al.
Publicado: (2019)

P39 Bloodstream infections (BSI) in tertiary ICU—an update!
por: Patel, Veer M., et al.
Publicado: (2022)

1576. Re-Evaluation of cefepime or piperacillin-tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales BloodStream Infections (REDUCE-BSI)
por: Vu, Catherine H, et al.
Publicado: (2020)

Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (REDUCE-BSI)
por: Vu, Catherine H., et al.
Publicado: (2022)

1187. Evaluation of an Antimicrobial Stewardship (AS) Bundle for Uncomplicated Gram-Negative Bloodstream Infections (GN-BSI) in Adults at a Large Academic Health System
por: Dipietro, Juliana M, et al.
Publicado: (2023)

1005. HIV-Associated Bloodstream Infection (BSI): Trends Over 7 Years
por: Hooshmand, Babak, et al.
Publicado: (2018)

38. Predicting stenotrophomonas Maltophilia bloodstream Infections (BSI) in the Hematologic Malignancy Population
por: Karaba, Sara M, et al.
Publicado: (2020)

1964. Microbiological Outcomes With Plazomicin (PLZ) vs. Colistin (CST) in Patients With Bloodstream Infections (BSI) Caused by Carbapenem-Resistant Enterobacteriaceae (CRE) in the CARE Study
por: Serio, Alisa W, et al.
Publicado: (2018)

165. Cefiderocol Treatment for Serious Infections Caused by Carbapenem-resistant Bacteria: Post-hoc Analysis of Outcomes by Pathogen in the CREDIBLE-CR Study
por: Matsunaga, Yuko, et al.
Publicado: (2020)

Healthcare-associated (HA) bloodstream infections (BSI) secondary top surgical site infections: surveillance program across Quebec hospitals (2007 to 2010)
por: Blouin, V, et al.
Publicado: (2011)

855 Risk Factors for Peripherally Inserted Central Catheter (PICC) Bloodstream Infection (BSI)
por: Kagan, Evgenia, et al.
Publicado: (2014)

1643. Pharmacodynamics (PD) of Daptomycin (DAP) in Combination Therapy for Enterococcal Bloodstream Infection (BSI)
por: Avery, Lindsay, et al.
Publicado: (2018)

Data on U.S. state-level electric vehicle policies, 2010–2015
por: Wee, Sherilyn, et al.
Publicado: (2019)

14-Year Survey in a Swedish County Reveals a Pronounced Increase in Bloodstream Infections (BSI). Comorbidity - An Independent Risk Factor for Both BSI and Mortality
por: Holmbom, Martin, et al.
Publicado: (2016)

1041. How Do Healthcare Providers Approach Empiric β-Lactam (BL) Treatment of Bloodstream Infections (BSI) Caused by Gram-Negative Rods (GNRs)? Analysis of Escherichia coli and Klebsiella pneumoniae BSI From the Veterans Health Administration (VHA)
por: Viau, Roberto, et al.
Publicado: (2018)

216. Association Between Days to Initiate Appropriate Therapy and Hospital Length of Stay Among Adult Hospitalized Patients With Gram-negative Bloodstream Infections (GN-BSI)
por: Lodise, Thomas, et al.
Publicado: (2019)

1292. Safety Profile of the Novel Siderophore Cephalosporin Cefiderocol in Randomized Phase 2 and Phase 3 Clinical Studies of Serious Gram-Negative Infections
por: Matsunaga, Yuko, et al.
Publicado: (2020)

2163 Polypharmacy and patterns of prescription medication use among cancer survivors
por: Murphy, Caitlin, et al.
Publicado: (2018)

912. Impact of Rapid Identification and Stewardship Intervention on Coagulase-negative Staphylococcus Bloodstream Infection (BSI)
por: Goshorn, Eli S, et al.
Publicado: (2022)

Changing Trends in Antimicrobial Susceptibility Patterns of Bloodstream Infection (BSI) in Secondary Care Hospitals of India
por: Karuna, T, et al.
Publicado: (2023)

Combination Vancomycin/Cefazolin (VAN/CFZ) for Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI)
por: Trinh, Trang D, et al.
Publicado: (2017)

171. Rising Rates of Gram-Negative Bacilli Blood Stream (GNB-BSI) Infection in Adults
por: Johnson, Leonard B, et al.
Publicado: (2019)

A targeted methicillin-resistant Staphylococcus aureus (MRSA) control program did not affect total nosocomial Staphylococcus aureus (SA) bloodstream infections (BSI) despite reducing MRSA BSI
por: Amri, B, et al.
Publicado: (2011)

90. Impact of Discrepant Rapid Diagnostic Test (RDT) Results on Antimicrobial Stewardship Program (ASP) Interventions in Patients with Bloodstream Infections (BSI) due to Gram-Negative Bacilli (GNB)
por: Robinson, Evan D, et al.
Publicado: (2020)

The relationship between minimum inhibitory concentration and 28 day mortality in patients with a Gram-negative bloodstream infection: an analysis of data from a cohort study (BSI-FOO)
por: Evans, Rebecca N, et al.
Publicado: (2023)

LB4. Efficacy and Safety of Cefiderocol vs. High-Dose Meropenem in Patients with Nosocomial Pneumonia—Results of a Phase 3, Randomized, Multicenter, Double-Blind, Non-Inferiority Study
por: Wunderink, Richard G, et al.
Publicado: (2019)

195. Reducing Time to Optimal Antimicrobial Therapy (OAT) for Bloodstream Infections (BSI) due to Gram Positive Cocci (GPC) in Chains Using Rapid Diagnostics Paired with Antimicrobial Stewardship (ASP) Efforts
por: Ma, Justin K, et al.
Publicado: (2022)

In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions
por: Pfaller, Michael A., et al.
Publicado: (2017)

Impact of bloodstream infections caused by carbapenem-resistant Gram-negative pathogens on ICU costs, mortality and length of stay
por: Kousouli, E., et al.
Publicado: (2019)

A 21-Year Survey of Escherichia coli from Bloodstream Infections (BSI) in a Tertiary Hospital Reveals How Community-Hospital Dynamics of B2 Phylogroup Clones Influence Local BSI Rates
por: Rodríguez, Irene, et al.
Publicado: (2021)

Catheter Related Bloodstream Infection (CR-BSI) in ICU Patients: Making the Decision to Remove or Not to Remove the Central Venous Catheter
por: Deliberato, Rodrigo Octávio, et al.
Publicado: (2012)

Risk Factors and Outcomes for Bloodstream Infections (BSI) Among Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
por: Rybak, Michael J, et al.
Publicado: (2017)

1596. Impact of Vancomycin Area Under Curve on Persistent Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI)
por: Alosaimy, Sara, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_scre5hsmgllhjoo5dni261d7k0